CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 4, 2001--Dyax Corp. (Nasdaq: DYAX - news) today announced the issuance of US Patent No. 6,326,155 entitled ``Engineering Affinity Ligands for Macromolecules.'' This patent relates to methods for identifying affinity ligands to purify biological molecules. Affinity ligands are used to isolate desired biological products from impurities generated during product manufacturing. The patented method can be used in combination with Dyax's proprietary phage display technology, making it a powerful biological purification process discovery and development tool.
``We are excited to add this important patent to our existing patent portfolio as it extends Dyax's ability to provide solutions to the biopharmaceutical industry. Biological therapeutics comprise the fastest growing segment of the worldwide pharmaceutical industry, and Dyax is very well positioned to help manufacturers increase effective capacity, improve efficiency, and meet the stringent criteria required for the purification of human therapeutics,'' said Henry E. Blair, Chairman and CEO of Dyax Corp.
Dyax is a pioneer in affinity ligand discovery and process development. Dyax uses its technology to discover affinity ligands that have high specificity to manufacturers' therapeutic antibodies, proteins, and peptides under optimized operating conditions. An affinity ligand can reduce the number of purification steps required and potentially improves product purity, cost, and yield. Dyax has demonstrated these capabilities by successfully identifying a number of affinity ligands, some of which are currently being used by Dyax's customers to manufacture clinical-grade therapeutics. |
